Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
27/02/2025
ASIT 2025: APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance
27/02/2025
ASIT 2025: APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance in Mouse Models of Autoimmune Disease
04/12/2024
Personalized Cancer Vaccine Summit – 2024 | Nykode’s individualized cancer vaccine approach across DNA and mRNA
12/11/2024
SITC 2024: A mRNA-LNP encoded APC-targeting neoantigen vaccine elicits stronger and broader T cell responses, and superior tumor control
07/11/2024
PEGS Europe 2024: APC-Targeted Vaccines Deliver Ag-specific Tolerance in Mouse Models of Autoimmunity
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
